{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:32:59Z","timestamp":1784345579641,"version":"3.55.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropeptides"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.npep.2021.102127","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T19:01:56Z","timestamp":1612292516000},"page":"102127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Combination therapy with neuropeptides for the treatment of anxiety disorder"],"prefix":"10.1016","volume":"86","author":[{"given":"Priti Ramakant","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kedar","family":"Prabhavalkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.npep.2021.102127_bb0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0893-133X(00)00182-2","article-title":"Dose response of arginine vasopressin to the CCK-B agonist pentagastrin","volume":"24","author":"Abelson","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.npep.2021.102127_bb0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0167-0115(00)00196-8","article-title":"Vasopressinergic regulation of the hypothalamic\u2013pituitary\u2013adrenal axis: implications for stress adaptation","volume":"96","author":"Aguilera","year":"2000","journal-title":"Regul. Pept."},{"key":"10.1016\/j.npep.2021.102127_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/S0031-9384(98)00119-X","article-title":"Vasopressin administration modulates anxiety-related behavior in rats","author":"Appenrodt","year":"1998","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.npep.2021.102127_bb0020","doi-asserted-by":"crossref","first-page":"327","DOI":"10.31887\/DCNS.2015.17.3\/bbandelow","article-title":"Epidemiology of anxiety disorders in the 21st century","volume":"17","author":"Bandelow","year":"2015","journal-title":"Dialogues Clin. Neurosci."},{"issue":"5","key":"10.1016\/j.npep.2021.102127_bb0025","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/15622975.2016.1181783","article-title":"Biological markers for anxiety disorders, OCD and PTSD - a consensus statement. Part I: neuroimaging and genetics","volume":"17","author":"Bandelow","year":"2016","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.npep.2021.102127_bb0030","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/15622975.2016.1190867","article-title":"Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: neurochemistry, neurophysiology and neurocognition","volume":"18","author":"Bandelow","year":"2017","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.npep.2021.102127_bb0035","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1146\/annurev.pa.28.040188.001441","article-title":"Regulation of the release of coexisting neurotransmitters","volume":"28","author":"Bartfai","year":"1988","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.npep.2021.102127_bb0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1755-5949.2009.00116.x","article-title":"A review of the neural mechanisms of action and clinical efficiency of Riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?","volume":"17","author":"Bellingham","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.npep.2021.102127_bb0045","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00213-008-1354-x","article-title":"Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior","volume":"202","author":"Bleickardt","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.npep.2021.102127_bb0050","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/j.1460-9568.2008.06397.x","article-title":"Orexin B\/hypocretin 2 increases glutamatergic transmission to ventral tegmental area neurons","volume":"28","author":"Borgland","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.npep.2021.102127_bb0055","doi-asserted-by":"crossref","DOI":"10.1007\/BF00212323","article-title":"Intra- and extrahypothalamic vasopressin and oxytocin pathways in the rat","volume":"192","author":"Buijs","year":"1978","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.npep.2021.102127_bb0060","series-title":"OxytocinSynthesis, Secretion, and Reproductive Functions. Knobil Neill\u2019s Physiol. Reprod","first-page":"3055","author":"Burbach","year":"2006"},{"key":"10.1016\/j.npep.2021.102127_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.tins.2012.12.010","article-title":"Neuronal plasticity and antidepressant actions","author":"Castr\u00e9n","year":"2013","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.npep.2021.102127_bb0070","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00213-009-1741-y","article-title":"Neuropeptide Y (NPY) suppresses yohimbine-induced reinstatement of alcohol seeking","volume":"208","author":"Cippitelli","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.npep.2021.102127_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/3738015","article-title":"Neural plasticity and neurogenesis in mental disorders","volume":"2016","author":"Cocks","year":"2016","journal-title":"Neural Plast"},{"key":"10.1016\/j.npep.2021.102127_bb0080","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2005.04.043","article-title":"Riluzole augmentation in treatment-resistant obsessive\u2013compulsive disorder: an open-label trial","volume":"58","author":"Coric","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.npep.2021.102127_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2011.03.003","article-title":"Neuroanatomical evidence for reciprocal regulation of the corticotrophin-releasing factor and oxytocin systems in the hypothalamus and the bed nucleus of the stria terminalis of the rat: implications for balancing stress and affect","author":"Dabrowska","year":"2011","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.npep.2021.102127_bb0090","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biopsych.2010.06.019","article-title":"Mood disorder susceptibility gene CACNA1C modifies mood-related behaviors in mice and interacts with sex to influence behavior in mice and diagnosis in humans","volume":"68","author":"Dao","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.npep.2021.102127_bb0095","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41386-018-0311-6","article-title":"Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis","volume":"44","author":"Davies","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.npep.2021.102127_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40495-019-00207-3","article-title":"Possible benefits of considering glutamate with melatonin or orexin or oxytocin as a combination approach in the treatment of anxiety","volume":"6","author":"Dhangar","year":"2020","journal-title":"Curr. Pharmacol. Rep."},{"key":"10.1016\/j.npep.2021.102127_bb0105","series-title":"Summary of Product Characteristics (SmPC) - (emc)","author":"Diazepam Tablets BP 10mg","year":"2021"},{"key":"10.1016\/j.npep.2021.102127_bb0110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12967-017-1237-1","article-title":"Xenon in the treatment of panic disorder: an open label study","volume":"15","author":"Dobrovolsky","year":"2017","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.npep.2021.102127_bb0115","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1113\/jphysiol.2006.124958","article-title":"Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block","volume":"581","author":"Dravid","year":"2007","journal-title":"J. Physiol."},{"key":"10.1016\/j.npep.2021.102127_bb0120","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/s41380-019-0400-x","article-title":"Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function","volume":"24","author":"Duman","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.npep.2021.102127_bb0125","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/jps.23495","article-title":"Pharmacokinetics and metabolism of SRX246: A potent and selective vasopressin 1a antagonist","volume":"102","author":"Fabio","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.npep.2021.102127_bb0130","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.tins.2015.06.005","article-title":"Orexins and fear: implications for the treatment of anxiety disorders","volume":"38","author":"Flores","year":"2015","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.npep.2021.102127_bb0135","series-title":"Summary of Product Characteristics (SmPC) - (emc)","author":"Fluoxetine 20 mg Capsules","year":"2021"},{"key":"10.1016\/j.npep.2021.102127_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2018.05.009","article-title":"Ketamine facilitates extinction of avoidance behavior and enhances synaptic plasticity in a rat model of anxiety vulnerability: implications for the pathophysiology and treatment of anxiety disorders","author":"Fortress","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.npep.2021.102127_bb0145","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/ijnp\/pyx116","article-title":"Role of 5-HT1A receptor stimulation in the medial prefrontal cortex in the sustained antidepressant effects of ketamine","volume":"21","author":"Fukumoto","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.npep.2021.102127_bb0150","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1742-7843.2008.00210.x","article-title":"Chronic administration of ketamine elicits antidepressant-like effects in rats without affecting hippocampal brain-derived neurotrophic factor protein levels","volume":"103","author":"Garcia","year":"2008","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.npep.2021.102127_bb0155","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.euroneuro.2009.01.011","article-title":"Research in anxiety disorders: from the bench to the bedside","volume":"19","author":"Garner","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.npep.2021.102127_bb0160","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-019-0415-8","article-title":"Orexin in the anxiety spectrum: association of a HCRTR1 polymorphism with panic disorder\/agoraphobia, CBT treatment response and fear-related intermediate phenotypes","volume":"9","author":"Gottschalk","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.npep.2021.102127_bb0165","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.yfrne.2018.06.003","article-title":"Orexins and stress","volume":"51","author":"Grafe","year":"2018","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.npep.2021.102127_bb0170","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0273-17.2018","article-title":"Reduced orexin system function contributes to resilience to repeated social stress","author":"Grafe","year":"2018","journal-title":"ENeuro"},{"key":"10.1016\/j.npep.2021.102127_bb0175","doi-asserted-by":"crossref","DOI":"10.1038\/nrd3702","article-title":"Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?","author":"Griebel","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.npep.2021.102127_bb0180","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/nrd3702","article-title":"Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?","volume":"11","author":"Griebel","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.npep.2021.102127_bb0185","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00441-018-2902-2","article-title":"Brain neuropeptide S: via GPCR activation to a powerful neuromodulator of socio-emotional behaviors","volume":"375","author":"Grund","year":"2019","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.npep.2021.102127_bb0190","doi-asserted-by":"crossref","first-page":"12214","DOI":"10.1523\/JNEUROSCI.2161-17.2017","article-title":"Neuropeptide S activates paraventricular oxytocin neurons to induce Anxiolysis","volume":"37","author":"Grund","year":"2017","journal-title":"J. Neurosci."},{"key":"10.1016\/j.npep.2021.102127_bb0195","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/jcm7020017","article-title":"Upping the care on downers: the evidence of risks, benefits and alternatives","volume":"7","author":"Guina","year":"2018","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.npep.2021.102127_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2018.00246","article-title":"Long-term isolation elicits depression and anxiety-related behaviors by reducing oxytocin-induced GABAergic transmission in central amygdala","volume":"11","author":"Han","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.npep.2021.102127_bb0205","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/00000542-199310000-00021","article-title":"Propofol activates GABAA receptor-chloride ionophore complex in dissociated hippocampal pyramidal neurons of the rat","volume":"79","author":"Hara","year":"1993","journal-title":"Anesthesiology"},{"key":"10.1016\/j.npep.2021.102127_bb0210","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.neuroscience.2010.06.003","article-title":"Immunohistochemical evidence for synaptic release of glutamate from orexin terminals in the locus coeruleus","volume":"169","author":"Henny","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.npep.2021.102127_bb0215","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejphar.2014.02.027","article-title":"Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior","volume":"730","author":"Hodgson","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.npep.2021.102127_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fncir.2018.00106","article-title":"Neuropeptide and small transmitter coexistence: fundamental studies and relevance to mental illness","volume":"12","author":"H\u00f6kfelt","year":"2018","journal-title":"Front Neural Circuits"},{"issue":"308","key":"10.1016\/j.npep.2021.102127_bb0225","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1126\/science.1105636","article-title":"Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala","volume":"80","author":"Huber","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.npep.2021.102127_bb0230","series-title":"Pulse Int","first-page":"4","volume":"17","author":"Investing in treatment for depression and anxiety leads to fourfold return","year":"2016"},{"key":"10.1016\/j.npep.2021.102127_bb0235","series-title":"Role of the Orexin\/Hypocretin System in Stress-Related Psychiatric Disorders. Curr. Top. Behav. Neurosci","first-page":"197","volume":"vol. 33","author":"James","year":"2017"},{"key":"10.1016\/j.npep.2021.102127_bb0240","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nm.2075","article-title":"A key role for orexin in panic anxiety","volume":"16","author":"Johnson","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.npep.2021.102127_bb0245","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-9554-7_1","article-title":"Enhancing the utility of preclinical research in neuropsychiatry drug development","author":"Kaffman","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.npep.2021.102127_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.npep.2009.11.010","article-title":"Neuronal circuits involving ghrelin in the hypothalamus-mediated regulation of feeding","author":"Kageyama","year":"2010","journal-title":"Neuropeptides"},{"key":"10.1016\/j.npep.2021.102127_bb0255","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0149-7634(01)00066-5","article-title":"The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y","volume":"26","author":"Kask","year":"2002","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.npep.2021.102127_bb0260","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1113\/jphysiol.2009.176297","article-title":"Memantine binding to a superficial site on NMDA receptors contributes to partial trapping","volume":"587","author":"Kotermanski","year":"2009","journal-title":"J. Physiol."},{"key":"10.1016\/j.npep.2021.102127_bb0265","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000496294","article-title":"Could dietary glutamate play a role in psychiatric distress?","volume":"79","author":"Kraal","year":"2020","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.npep.2021.102127_bb0270","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.biopsych.2017.03.007","article-title":"It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: a consensus statement of the PTSD psychopharmacology working group","volume":"82","author":"Krystal","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.npep.2021.102127_bb0275","first-page":"973","article-title":"Anxiolytic-like profile of propofol, a general anesthetic, in the plus-maze test in mice","volume":"55","author":"Kurt","year":"2003","journal-title":"Pol. J. Pharmacol."},{"key":"10.1016\/j.npep.2021.102127_bb0280","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2174\/187152706776359664","article-title":"The involvement of the vasopressin system in stress-related disorders","volume":"5","author":"Landgraf","year":"2006","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.npep.2021.102127_bb0285","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/mp.2012.71","article-title":"Forebrain elimination of cacna1c mediates anxiety-like behavior in mice","volume":"17","author":"Lee","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.npep.2021.102127_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fnsys.2013.00100","article-title":"A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study","volume":"7","author":"Lee","year":"2013","journal-title":"Front. Syst. Neurosci."},{"key":"10.1016\/j.npep.2021.102127_bb0295","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.biopsych.2015.05.003","article-title":"Intranasal oxytocin: myths and delusions","volume":"79","author":"Leng","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.npep.2021.102127_bb0300","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.brainres.2014.01.025","article-title":"Oxytocin\u2019s role in anxiety: A critical appraisal","volume":"1580","author":"MacDonald","year":"2014","journal-title":"Brain Res."},{"key":"10.1016\/j.npep.2021.102127_bb0305","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-012-2681-5","article-title":"Interactions between VTA orexin and glutamate in cue-induced reinstatement of cocaine seeking in rats","author":"Mahler","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.npep.2021.102127_bb0310","doi-asserted-by":"crossref","DOI":"10.1046\/j.1365-2826.2000.00451.x","article-title":"Differential regulation of neuropeptide Y mRNA expression in the arcuate nucleus and locus coeruleus by stress and antidepressants","author":"Makino","year":"2000","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.npep.2021.102127_bb0315","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archpsyc.55.8.715","article-title":"Decreased brain GABAA-benzodiazepine receptor binding in panic disorder","volume":"55","author":"Malizia","year":"1998","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.npep.2021.102127_bb0320","doi-asserted-by":"crossref","first-page":"17143","DOI":"10.1523\/JNEUROSCI.1040-12.2012","article-title":"Anxiety-like behavior of prenatally stressed rats is associated with a selective reduction of glutamate release in the ventral Hippocampus","volume":"32","author":"Marrocco","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.npep.2021.102127_bb0325","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1523\/JNEUROSCI.4131-13.2014","article-title":"The effects of antidepressant treatment in prenatally stressed rats support the glutamatergic hypothesis of stress-related disorders","volume":"34","author":"Marrocco","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.npep.2021.102127_bb0330","doi-asserted-by":"crossref","first-page":"281","DOI":"10.31887\/DCNS.2003.5.3\/pmartin","article-title":"The epidemiology of anxiety disorders: a review","volume":"5","author":"Martin","year":"2003","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.npep.2021.102127_bb0335","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1176\/appi.ajp.162.12.2379","article-title":"Open-label trial of riluzole in generalized anxiety disorder","volume":"162","author":"Mathew","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.npep.2021.102127_bb0340","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1038\/npp.2017.106","article-title":"A randomized, double-blind, placebo-controlled, sequential parallel comparison design trial of adjunctive Riluzole for treatment-resistant major depressive disorder","volume":"42","author":"Mathew","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.npep.2021.102127_bb0345","first-page":"93","article-title":"Orexina, regolazione del sonno e dell\u2019appetito: Una rassegna","volume":"156","author":"Mazza","year":"2005","journal-title":"Clin. Ter."},{"key":"10.1016\/j.npep.2021.102127_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106189","article-title":"Xenon impairs reconsolidation of fear memories in a rat model of post-traumatic stress disorder (PTSD)","volume":"9","author":"Meloni","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.npep.2021.102127_bb0355","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.brainres.2009.09.077","article-title":"A possible role of neuropeptide Y in depression and stress","volume":"1314","author":"Morales-Medina","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.npep.2021.102127_bb0360","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11920-017-0819-1","article-title":"Oxytocin and anxiety disorders: translational and therapeutic aspects","volume":"19","author":"Naja","year":"2017","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.npep.2021.102127_bb0365","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1471-4159.2012.07895.x","article-title":"Exposure to predator odor and resulting anxiety enhances the expression of the \u03b1 2 \u03b4 subunit of voltage-sensitive calcium channels in the amygdala","volume":"125","author":"Nasca","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.npep.2021.102127_bb0370","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0079-6123(02)39014-9","article-title":"Chapter 12 Involvement of the brain oxytocin system in stress coping: interactions with the hypothalamo-pituitary-adrenal axis","author":"Neumann","year":"2002","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.npep.2021.102127_bb0375","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.tins.2012.08.004","article-title":"Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors","volume":"35","author":"Neumann","year":"2012","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.npep.2021.102127_bb0380","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.biopsych.2015.06.004","article-title":"Oxytocin in general anxiety and social fear: a translational approach","volume":"79","author":"Neumann","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.npep.2021.102127_bb0385","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/hup.2237","article-title":"Oxytocin interference in the effects induced by inhalation of 7.5% CO2 in healthy volunteers","volume":"27","author":"Oliveira","year":"2012","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.npep.2021.102127_bb0390","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neuropharm.2009.06.001","article-title":"Neuropeptide S: a transmitter system in the brain regulating fear and anxiety","volume":"58","author":"Pape","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.npep.2021.102127_bb0395","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1523\/JNEUROSCI.5724-09.2010","article-title":"Hypocretins regulate the anxiogenic-like effects of nicotine and induce reinstatement of nicotine-seeking behavior","volume":"30","author":"Plaza-Zabala","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.npep.2021.102127_bb0400","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1369-1600.2012.00439.x","article-title":"Oxytocin regulates changes of extracellular glutamate and GABA levels induced by methamphetamine in the mouse brain","volume":"17","author":"Qi","year":"2012","journal-title":"Addict. Biol."},{"key":"10.1016\/j.npep.2021.102127_bb0405","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1517\/13543784.2014.986264","article-title":"Novel metabotropic glutamate receptor 4 and glutamate receptor 8 therapeutics for the treatment of anxiety","volume":"24","author":"Raber","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.npep.2021.102127_bb0410","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1023\/A:1007648229795","article-title":"Synaptosomes still viable after 25 years of superfusion","volume":"25","author":"Raiteri","year":"2000","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.npep.2021.102127_bb0415","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/wps.20611","article-title":"Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders","volume":"18","author":"Reed","year":"2019","journal-title":"World Psychiatry"},{"key":"10.1016\/j.npep.2021.102127_bb0420","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.npep.2015.09.008","article-title":"Neuropeptide Y: a stressful review","volume":"55","author":"Reichmann","year":"2016","journal-title":"Neuropeptides"},{"key":"10.1016\/j.npep.2021.102127_bb0425","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/NMD.0b013e3181fe75dc","article-title":"Prevalence of depression, anxiety, and stress among young male adults in India","volume":"198","author":"Sahoo","year":"2010","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.npep.2021.102127_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.orcp.2013.12.001","article-title":"Roles of orexins in the regulation of body weight homeostasis","author":"Sakurai","year":"2014","journal-title":"Obes. Res. Clin. Pract."},{"key":"10.1016\/j.npep.2021.102127_bb0435","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.tips.2011.03.007","article-title":"Connectomics of orexin-producing neurons: Interface of systems of emotion, energy homeostasis and arousal","volume":"32","author":"Sakurai","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.npep.2021.102127_bb0440","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-006-0424-1","article-title":"Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats","author":"Salom\u00e9","year":"2006","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/j.npep.2021.102127_bb0445","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1176\/appi.ajp.161.11.2132","article-title":"Riluzole augmentation for treatment-resistant depression","volume":"161","author":"Sanacora","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.npep.2021.102127_bb0450","doi-asserted-by":"crossref","first-page":"107402","DOI":"10.1016\/j.pharmthera.2019.107402","article-title":"Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders","volume":"204","author":"Sartori","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.npep.2021.102127_bb0455","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ijnp\/pyx109","article-title":"A randomized dose-ranging study of neuropeptide Y in patients with posttraumatic stress disorder","volume":"21","author":"Sayed","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.npep.2021.102127_bb0460","series-title":"Summary of Product Characteristics (SmPC) - (emc)","author":"Sertraline 50mg tablets","year":"2021"},{"key":"10.1016\/j.npep.2021.102127_bb0465","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/npp.2009.83","article-title":"The neurocircuitry of fear, stress, and anxiety disorders","volume":"35","author":"Shin","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.npep.2021.102127_bb0470","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1749-6632.2003.tb07078.x","article-title":"L-type voltage-gated calcium channels are involved in the in vivo and in vitro expression of fear conditioning","volume":"985","author":"Shinnick-Gallagher","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.npep.2021.102127_bb0475","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.psyneuen.2015.09.017","article-title":"Local oxytocin tempers anxiety by activating GABAA receptors in the hypothalamic paraventricular nucleus","volume":"63","author":"Smith","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.npep.2021.102127_bb0480","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.yfrne.2017.10.004","article-title":"Cross-talk among oxytocin and arginine-vasopressin receptors: relevance for basic and clinical studies of the brain and periphery","volume":"51","author":"Song","year":"2018","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.npep.2021.102127_bb0485","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.neuropharm.2018.09.016","article-title":"Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression","volume":"143","author":"Staton","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.npep.2021.102127_bb0490","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.npp.1300562","article-title":"Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415","volume":"30","author":"Stemmelin","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.npep.2021.102127_bb0495","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/j.neuropharm.2012.02.012","article-title":"Riluzole produces distinct anxiolytic-like effects in rats without the adverse effects associated with benzodiazepines","volume":"62","author":"Sugiyama","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.npep.2021.102127_bb0500","first-page":"146085","article-title":"Orexin\/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: potential for therapy","volume":"2020","author":"Summers","year":"1731","journal-title":"Brain Res."},{"key":"10.1016\/j.npep.2021.102127_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2005.03.002","article-title":"Orexin-A (hypocretin-1) is possibly involved in generation of anxiety-like behavior","author":"Suzuki","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.npep.2021.102127_bb0510","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1523\/JNEUROSCI.2944-18.2019","article-title":"Oxytocin receptors are expressed by glutamatergic prefrontal cortical neurons that selectively modulate social recognition","volume":"39","author":"Tan","year":"2019","journal-title":"J. Neurosci."},{"key":"10.1016\/j.npep.2021.102127_bb0515","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1038\/npp.2015.147","article-title":"Oxytocin stimulates extracellular Ca2+ influx through TRPV2 channels in hypothalamic neurons to exert its anxiolytic effects","volume":"40","author":"van den Burg","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.npep.2021.102127_bb0520","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.bbr.2014.10.028","article-title":"The orexin-1 receptor antagonist SB-334867 decreases anxiety-like behavior and c-Fos expression in the hypothalamus of rats exposed to cat odor","volume":"278","author":"Vanderhaven","year":"2015","journal-title":"Behav. Brain Res."},{"issue":"333","key":"10.1016\/j.npep.2021.102127_bb0525","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.1201043","article-title":"Oxytocin selectively gates fear responses through distinct outputs from the central amygdala","volume":"80","author":"Viviani","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.npep.2021.102127_bb0530","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2147\/DDDT.S188636","article-title":"Neuroprotective potential of ketamine prevents developing brain structure impairment and alteration of neurocognitive function induced via isoflurane through the PI3K\/AKT\/GSK-3\u03b2 pathway","volume":"13","author":"Wang","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.npep.2021.102127_bb0535","series-title":"Anxiety Disord","first-page":"389","article-title":"Stress, Anxiety, and Depression and the Role of Glutamate Neurotransmission","author":"Williams","year":"2015"},{"key":"10.1016\/j.npep.2021.102127_bb0540","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1523\/JNEUROSCI.3432-03.2004","article-title":"Oxytocin attenuates stress-induced c-fos mRNA expression in specific forebrain regions associated with modulation of Hypothalamo-pituitary-adrenal activity","volume":"24","author":"Windle","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.npep.2021.102127_bb0545","doi-asserted-by":"crossref","first-page":"11439","DOI":"10.1523\/JNEUROSCI.3459-04.2004","article-title":"Interaction between the corticotropin-releasing factor system and hypocretins (orexins): A novel circuit mediating stress response","volume":"24","author":"Winsky-Sommerer","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.npep.2021.102127_bb0550","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1517\/14728222.2011.628314","article-title":"Central functions of neuropeptide Y in mood and anxiety disorders","volume":"15","author":"Wu","year":"2011","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.npep.2021.102127_bb0555","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.neuron.2004.08.005","article-title":"Neuropeptide S","volume":"43","author":"Xu","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.npep.2021.102127_bb0560","first-page":"1","article-title":"Another side of the antidiuretic hormone, vasopressin: its role in stress regulation","volume":"1","author":"Zelena","year":"2010","journal-title":"J. Exp. Sci."},{"key":"10.1016\/j.npep.2021.102127_bb0565","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5492\/wjccm.v1.i3.80","article-title":"General anesthesia mediated by effects on ion channels","volume":"1","author":"Zhou","year":"2012","journal-title":"World J. Crit. Care Med."},{"key":"10.1016\/j.npep.2021.102127_bb0570","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1523\/JNEUROSCI.1547-16.2016","article-title":"Ketamine: NMDA receptors and beyond","volume":"36","author":"Zorumski","year":"2016","journal-title":"J. Neurosci."}],"container-title":["Neuropeptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143417921000135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143417921000135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T20:37:38Z","timestamp":1758919058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0143417921000135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":114,"alternative-id":["S0143417921000135"],"URL":"https:\/\/doi.org\/10.1016\/j.npep.2021.102127","relation":{},"ISSN":["0143-4179"],"issn-type":[{"value":"0143-4179","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapy with neuropeptides for the treatment of anxiety disorder","name":"articletitle","label":"Article Title"},{"value":"Neuropeptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.npep.2021.102127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102127"}}